Lotrich and Pollock Mori S, Garbini S, Caivano M, et al. 1998. Time-course changes in rat cerebral cortex subcellular distribution of the cyclic-AMP binding after treatment with selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol, 1:3–10. Mossner R, Daniel S, Albert D, et al. 2000. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int, 36:197–202. Mundo E, Tharmalingham S, Neves-Pereira M, et al. 2003. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry, 8:241–5. Mundo E, Walker M, Cate T, et al. 2001. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry, 58:539–44. Murphy DL, Uhl GR, Holmes A, et al. 2003. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav, 2:359–64. Murphy GM, Kremer C, Rodrigues H, et al. 2003a. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry, 54:665–73. Murphy GM Jr, Kremer C, Rodrigues HE, et al. 2003b. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry, 160: 1830–5. Nakamura M, Ueno S, Sano A, et al. 2000. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry, 5:32–8. Nestler EJ, Terwilliger RZ, Duman RS. 1989. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP- dependent protein kinase in rat frontal cortex. J Neurochem, 53: 1644–7. Neves-Pereira M, Mundo E, Muglia P, et al. 2002. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet, 71:651–5. Newton SS, Thome J, Wallace TL, et al. 2002. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci, 24:10883–90. Ni X, Trakalo JM, Mundo E, et al. 2002. Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder. Biol Psychiatry, 52:1144–50. Nibuya M, Morinobu S, Duman RS. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci, 15:7539–47. Nibuya M, Nestler EJ, Duman RS. 1996. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci, 16: 2365–72. Nierenberg AA. 2003. Predictors of response to antidepressants general principles and clinical implications. Psychiatr Clin North Am, 26: 345–52. Nierenberg AA, DeCecco LM. 2001. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry, 62:5–9. Niesler B, Flohr T, Nothen MM, et al. 2001. Association between the 5´ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics, 11:471–5. Nunoki K, Florio V, Catterall WA. 1989. Activation of purified calcium channels by stoichiometric protein phosphorylation. Proc Natl Acad Sci U S A, 86:6818–20. Nurnberger J, Dammer S, Mitchell A, et al. 2003. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Therap, 74:53–60. Odagaki Y, Garcia-Sevilla JA, Huguelet P, et al. 2001. Cyclic AMP- mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims. Brain Res, 898:224–31. Ordway GA, Klimek V, Mann JJ. 2002. Neurocircuitry of mood disorders. Davis KL, Charney D, Coyle JT, et al (eds). Neuropsycho- pharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Williams. p 1051–64. O’Reilly RL, Bogue L, Singh SM. 1994. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry, 36:467–71. Pandey SC, Carr LG, Heilig M, et al. 2003. Neuropeptide Y and alcoholism: genetic, molecular, and pharmacological evidence. Alcohol Clin Exp Res, 27:149–54. Papadimitriou GN, Dikeos DG, Souery D, et al. 2003. Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study. Psychiatr Genet, 13:211–20. Pare CM, Mack JW. 1971. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet, 8:306–9. Parker G, Anderson IM, Haddad P. 2002. Clinical trials of antidepressant medications are producing meaningless results. Br J Psychiatry, 183:102–4. Patel PD, Pontrello C, Burke S. 2004. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol Psychiatry, 55:428–33. Perez J, Tinelli D, Bianchi E, et al. 1991. cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NE reuptake blockers with antidepressant activity. Neuropsychopharmacology, 4:57–64. Phillips TJ. 1997. Behavior genetics of drug sensitization. Crit Rev Neurobiol, 11:21–33. Pickar D, Rubinow K. 2001. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci, 22:75–83. Pilc A, Branski P, Palucha A, et al. 1999. The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/ calmodulin-dependent protein kinase II in the hippocampus of rat brain. Neuropharmacology, 38:597–603. Pliakas A, Carlson RR, Neve RL, et al. 2001. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated CREB expression in the nucleus accumbens. J Neurosci, 21:7397–403. Pollock BG, Ferrell RE, Mulsant BH, et al. 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology, 23: 587–90. Popoli M, Vocaturo C, Perez J, et al. 1995. Presynaptic Ca2+/calmodulin- dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Mol Pharmacol, 48:623–9. Price NE, Mumbly MC. 1999. Brain protein serine/threonine phosphatases. Curr Opin Neurobiol, 9:336–42. Qian Y, Galli A, Ramamoorthy S, et al. 1997. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci, 17:45–57. Qu Y, Chang L, Klaff J, et al. 2003a. Imaging of brain serotonergic neurotransmission involving phospholipase A2 activation and arachidonic acid release in unanesthetized rats. Brain Res Brain Res Protoc, 12:16–25. Qu Y, Chang L, Klaff J, et al. 2003b. Imaging brain phospholipase A2- mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology, 28:1219–26. Rahimian R, Hrdina PD. 1995. Possible role of protein kinase C in regulation of 5-hydroxytryptamine 2A receptors in rat brain. Can J Physiol Pharmacol, 73:1686–91. Rahman S, Li PP, Young LT, et al. 1997. Reduced [3H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem, 68:297–304. 32 Neuropsychiatric Disease and Treatment 2005:1(1)